Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05169619
Other study ID # D2287R00155
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 30, 2021
Est. completion date March 31, 2024

Study information

Verified date December 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to determine the prevalence of Asthma, Difficult-to-Treat and Severe Asthma in Portugal, and characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease.


Description:

Data on the epidemiology of asthma in Portugal were mainly grounded in studies using questionnaires and covering limited age groups. Studies assessing the prevalence of asthma diagnosis and of its sub-groups with more accurate methods are therefore needed This study aims to determine the prevalence of asthma, difficult-to-treat and severe asthma in Portugal, and to characterize patients to better understand their disease characteristics, treatment profile and health care resource use to improve clinical management of the disease. We will conduct a population-based nationwide study with a multicentre stepwise approach, enrolling 7500 adult subjects, randomly selected, from the Portuguese National Health Service patients' database of 38 primary care centres: STAGE 0 - Phone call invitation and enrolment of participants STAGE 1 - Telephone interview survey to assess respiratory symptoms. STAGE 2 - Clinical assessment, diagnostic confirmation, and patient characterization STAGE 3 - Characterization of asthma patients (sub-group) and characterization of difficult- to-treat asthma & severe asthma patients after 3 months follow up period.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 842
Est. completion date March 31, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults =>18 years old registered in Portuguese National Health service patients' database of primary care units. - Give voluntary signed informed consent, - Ability to understand ans answer questionnaires. Exclusion Criteria: - Participants that have a physical condition that could interfere with the study assessments or prevent the participant from adequately participating in the study (e.g. mobility problems, not able to perform spirometry,…)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Portugal Research Site Alpedorada
Portugal Research Site Arazede
Portugal Research Site Aveiro
Portugal Research Site Braga
Portugal Research Site Cascais
Portugal Research Site Coimbra
Portugal Research Site Evora
Portugal Research Site Fafe
Portugal Research Site Felgueiras
Portugal Research Site Gilao De Tavira
Portugal Research Site Horizonte -Matosinhos
Portugal Research Site Lagoa - Matosinhos
Portugal Research Site Leiria
Portugal Research Site Lisboa - Conchas
Portugal Research Site Lisboa - Olivais
Portugal Research Site Lisboa - Parque
Portugal Research Site Mafra
Portugal Research Site Massama
Portugal Research Site Oceanos - Matosinhos
Portugal Research Site Oeiras
Portugal Research Site Ovar
Portugal Research Site Pinhal Novo
Portugal Research Site Ponte
Portugal Research Site Porto
Portugal Research Site Quinta do Conde
Portugal Research Site Ria Formosa
Portugal Research Site Ribeiro De Pena
Portugal Research Site Rio de Mouro
Portugal Research Site Tomar
Portugal Research Site Tondela
Portugal Research Site Torres Vedras
Portugal Research Site Viana do Castelo
Portugal Research Site Vila do Conde
Portugal Research Site Vila Nova da Barquinha
Portugal Research Site Vila Nova de Gaia
Portugal Research Site Vila Real
Portugal Research Site Vouzela

Sponsors (3)

Lead Sponsor Collaborator
AstraZeneca Faculdade de Medicina da Universidade do Porto - CINTESIS, Universidade do Minho - ICVS

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with asthma, difficult-to-treat asthma, and severe asthma Ratio between the total number of participants with confirmed asthma, difficult-to-treat asthma, and severe asthma and the total number of participants From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Age Years From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Living in a city or rural community Postal code From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Family history Family history of asthma and asthma death and type of relationship From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Comorbidities and allergies List of comorbidities with major impact on asthma outcomes From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Obesity WHO classification of body mass index From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Physical activity Using the brief physical activity assessment questionnaire. This brief physical activity assessment has only two questions and subjects are scored on < 4 (Insufficiently" active) and ?4 ("Sufficiently" active). From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Health related quality of life Using mini AQLQ Questionnaire AQLQ is a multiple-choice questionnaire for patients with asthma, each choice is assigned a score 1-7. There are 15 questions to answer. The total score is calculated and ranges between 15 and 105. Lower scores indicate worse quality of life. From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Healthcare resource use and costs a) Direct resources will include number of inpatient admissions, emergency and hospital visits, medical appointments, diagnostic tests previously performed for asthma treatment in the last 12 months. b) Indirect resources will include reduced productivity of Asthma patients through an ad-hoc questionnaire about absenteeism (work and school days lost because of asthma) and presenteeism (reduced productivity due to asthma) in the last 12 months. From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Referral number of patients that should be referral for asthma specialist hospital Consultation or that were referred to Severe Asthma consultation From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Age of Asthma onset Age of Asthma onset From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Asthma symptoms According to Control of Allergic Rhinitis and Asthma Test (CARAT). CARAT is a 10-item validated Portuguese questionnaire, which allows for the simultaneous assessment of allergic rhinitis and asthma (ARA) control. A score above 24 (min. 0; max. 30) identifies controlled asthma. From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Pulmonary function tests Spirometry and reversibility testing From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Inflammatory biomarkers Fractional exhaled nitric oxide (FeNO) test and blood eosinophil and neutrophil count, From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Exacerbations Number of exacerbations in the past year From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Emergency room (ER) visits Number of visits to emergency room (ER) within the past year From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Hospital admissions Number of hospital admissions and mean length of hospital stay in the past year From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Disease Characteristics - Disease control According to Control of Allergic Rhinitis and Asthma Test (CARAT). CARAT is a 10-item validated Portuguese questionnaire, which allows for the simultaneous assessment of allergic rhinitis and asthma (ARA) control. A score above 24 (min. 0; max. 30) identifies controlled asthma. From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Treatment Patterns - Treatment profile (current and last year) Stage of GINA treatment step according to GINA guidelines From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Treatment Patterns - Treatment adherence Assessed using a Visual Analogue Scale (VAS) from 0 to 100, 0 means poor adherence and 100 good adherence From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Treatment Patterns - Inhalation technique Assessed by the clinician using national checklists From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Gender Male/Female From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Marital status Single, Married / De facto Union, Separated / Divorced, Widowed From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - socio-economic and education level From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - occupational status From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Smoking status & environmental tobacco smoke From date of inclusion until the end of the study currently planned (2,5 years)
Secondary Subject's characteristics - Health related quality of life Using EQ-5D. EQ-5D is a questionnaire which include five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). and is used to evaluate the quality of life. Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). There are 3,125 possible health states defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). From date of inclusion until the end of the study currently planned (2,5 years)
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device